Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that […]
Biosimilar Reverse Engineering: The Complete Technical, Regulatory, and IP Playbook Read Post »
Executive Summary Every month, the FDA issues a batch of Tentative Approvals (TAs) for generic drug applications. Most market participants
1. What Excipients Actually Are, and Why the Definition Undersells Them The word ‘excipient’ derives from the Latin excipere, meaning
Pharmaceutical Excipients: The Complete IP, Clinical, and Competitive Strategy Guide Read Post »
How European Supplementary Protection Certificates actually work, why their expiry dates keep moving, and what that means for your market
EU SPC Expiry Decoded: The Competitive Playbook Every Pharma Strategist Needs Read Post »
Executive Summary How to win 180-day exclusivity, survive the price erosion curve, and build a future-proof portfolio in a $491B
Generic Drug Launch Strategy: The Complete IP, Regulatory & Commercial Playbook Read Post »
I. The $300 Billion Opportunity Hiding in Plain Sight The most reliable, legally mandated, and fiscally massive cost-containment event in
Patent Cliff Playbook: How Payers Capture Billions from Drug LOE Events Read Post »
The 20-year patent term is the most cited number in pharmaceutical business strategy. It is also, in practice, a fiction.
Part I: The Exclusivity Architecture: What Executives Get Wrong About the 20-Year Rule The number ’20 years’ is the most
Pharma Patent Expiration Calendar: The Complete LOE Strategy Guide Read Post »
Why This Cliff Is Different Generic and biosimilar drugs saved the U.S. healthcare system an estimated $3.1 trillion over the
Patent Cliff Playbook: How Generic Firms Win $200B in Off-Patent Drug Markets Read Post »
Sign in or create a free account to read this DrugPatentWatch article
